Condition
Leukemia, Chronic Lymphatic
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed2
Withdrawn1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03204188Phase 2Completed
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02802943Phase 2CompletedPrimary
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
NCT04407845UnknownPrimary
Atrial Fibrillation in Patients Receiving Ibrutinib
NCT02020109WithdrawnPrimary
Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
Showing all 4 trials